| 1 | Liver stiffness progression in biopsy-proven metabolic dysfunction–associated steatotic disease among people with diabetes versus people without diabetes: A prospective multicenter study | 10.1 | 27 | Citations (PDF) |
| 2 | Prevalence of Chronic Liver Disease in Cholangiocarcinoma: A Meta-Analysis | 6.0 | 2 | Citations (PDF) |
| 3 | Prevalence of Low FIB‐4 in MASLD‐Related Hepatocellular Carcinoma: A Multicentre Study | 3.7 | 18 | Citations (PDF) |
| 4 | A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia | 3.7 | 20 | Citations (PDF) |
| 5 | Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis | 10.1 | 68 | Citations (PDF) |
| 6 | Burden of alcohol use disorder, alcohol-related liver disease, and alcohol-related liver cancer: Editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021 | 8.8 | 1 | Citations (PDF) |
| 7 | The Global Burden of Cirrhosis and Other Chronic Liver Diseases in 2021 | 4.0 | 37 | Citations (PDF) |
| 8 | Metabolic dysfunction-associated steatotic liver disease in adults | 47.2 | 187 | Citations (PDF) |
| 9 | Metabolic Cause of Cirrhosis Is the Emerging Etiology for Primary Liver Cancer in the Asia‐Oceania Region: Analysis of Global Burden of Disease (GBD) Study 2021 | 2.5 | 9 | Citations (PDF) |
| 10 | Global Health Policies for Hepatocellular Carcinoma: A Cross-Sectional Study | 6.0 | 2 | Citations (PDF) |
| 11 | Distribution, Characteristics, and Natural History of Diverse Types of Indeterminate Chronic Hepatitis B: A <scp>REAL</scp>‐B Study | 3.7 | 4 | Citations (PDF) |
| 12 | Meta‐Analysis: Effects of Steatotic Liver Disease‐Associated Genetic Risk Alleles on Longitudinal Outcomes | 3.7 | 11 | Citations (PDF) |
| 13 | NASH is the Leading Cause of Hepatocellular Carcinoma in Liver Transplant Candidates | 6.0 | 40 | Citations (PDF) |
| 14 | NAFLD and NAFLD-related HCC in Asia: Burden and Surveillance | 2.3 | 11 | Citations (PDF) |
| 15 | Low liver fat in non‐alcoholic steatohepatitis‐related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality | 3.7 | 23 | Citations (PDF) |
| 16 | Cost-Effectiveness Analysis of Hepatocellular Carcinoma Surveillance in Nonalcoholic Fatty Liver Disease Cirrhosis Using US Visualization Score C–Triggered Abbreviated MRI | 0.7 | 16 | Citations (PDF) |
| 17 | Racial and ethnic disparities in untreated patients with hepatitis C virus‐related hepatocellular carcinoma but not in those with sustained virologic response | 3.7 | 7 | Citations (PDF) |
| 18 | Meta‐analysis: Prevalence and impact of alcohol abstinence in alcohol‐associated cirrhosis | 3.7 | 19 | Citations (PDF) |
| 19 | Upper limit of normal ALT levels in health and metabolic diseases: Pooled analysis of 423,355 individuals with bootstrap modelling | 3.7 | 11 | Citations (PDF) |
| 20 | Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease | 2.9 | 20 | Citations (PDF) |
| 21 | Disparities among ethnic groups in mortality and outcomes among adults with MASLD: A multicenter study | 4.0 | 19 | Citations (PDF) |
| 22 | MASH Resolution Index: development and validation of a non-invasive score to detect histological resolution of MASH | 16.8 | 35 | Citations (PDF) |
| 23 | Changing global epidemiology of chronic hepatitis C virus-related outcomes from 2010 to 2019: cirrhosis is the growing burden of hepatitis C virus-related disease | 2.0 | 7 | Citations (PDF) |
| 24 | Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease | 3.7 | 7 | Citations (PDF) |
| 25 | Incidence of liver cancer in young adults according to the Global Burden of Disease database 2019 | 10.1 | 40 | Citations (PDF) |
| 26 | Repeatability of vibration‐controlled transient elastography versus magnetic resonance elastography in patients with cirrhosis: A prospective study | 3.7 | 8 | Citations (PDF) |
| 27 | Socio‐economic association of alcohol use disorder and cardiovascular and alcohol‐associated liver disease from 2010 to 2019 | 3.7 | 34 | Citations (PDF) |
| 28 | Optimizing care of HBV infection and HBV-related HCC | 1.3 | 1 | Citations (PDF) |
| 29 | Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions | 45.9 | 134 | Citations (PDF) |
| 30 | Outcomes of Nonalcoholic Steatohepatitis After Liver Transplantation: An Updated Meta-Analysis and Systematic Review | 6.0 | 43 | Citations (PDF) |
| 31 | Renal Outcomes With Tenofovir Alafenamide in Liver Transplant Recipients | 6.0 | 7 | Citations (PDF) |
| 32 | UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies | 6.0 | 68 | Citations (PDF) |
| 33 | Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis | 6.0 | 171 | Citations (PDF) |
| 34 | Future anti‐HDV treatment strategies, including those aimed at HBV functional cure | 4.0 | 9 | Citations (PDF) |
| 35 | Clinical Utility of Combined MRI-PDFF and ALT Response in Predicting Histologic Response in Nonalcoholic Fatty Liver Disease | 6.0 | 39 | Citations (PDF) |
| 36 | Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH | 10.1 | 125 | Citations (PDF) |
| 37 | Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis | 16.8 | 89 | Citations (PDF) |
| 38 | Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD | 3.7 | 52 | Citations (PDF) |
| 39 | Diabetes and Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease | 2.8 | 31 | Citations (PDF) |
| 40 | Meta‐analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin | 3.7 | 77 | Citations (PDF) |
| 41 | Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis | 10.1 | 16 | Citations (PDF) |
| 42 | The prognostic value of including non‐alcoholic fatty liver disease in the definition of metabolic syndrome | 3.7 | 23 | Citations (PDF) |
| 43 | Racial and Ethnic Disparities in Characteristics and Care Patterns of Chronic Hepatitis B Patients in the United States | 6.0 | 8 | Citations (PDF) |
| 44 | The Past, Present, and Future of Noninvasive Test in Chronic Liver Diseases | 3.1 | 3 | Citations (PDF) |
| 45 | Genomic analysis of lean individuals with NAFLD identifies monogenic disorders in a prospective cohort study | 4.5 | 20 | Citations (PDF) |
| 46 | A Pro-Regenerative Environment Triggers Premalignant to Malignant Transformation of Senescent Hepatocytes | 3.8 | 11 | Citations (PDF) |
| 47 | Global treatment rate and barriers to direct‐acting antiviral therapy: A systematic review and meta‐analysis of 146 studies and 1 760 352 hepatitis C virus patients | 4.0 | 15 | Citations (PDF) |
| 48 | Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how? | 8.8 | 3 | Citations (PDF) |
| 49 | Global epidemiology of cirrhosis — aetiology, trends and predictions | 45.9 | 681 | Citations (PDF) |
| 50 | Global burden of hepatitis B virus: current status, missed opportunities and a call for action | 45.9 | 496 | Citations (PDF) |
| 51 | Ethnic disparities in waitlist outcomes of patients with nonalcoholic steatohepatitis listed for liver transplantation in the US | 2.5 | 9 | Citations (PDF) |
| 52 | Utilization of Antiviral Therapy for Patients With Hepatitis B–Related Hepatocellular Carcinoma: A Nationwide Real-World US Study | 6.0 | 12 | Citations (PDF) |
| 53 | Meta‐analysis: Prevalence of significant or advanced fibrosis in adults with alpha‐1‐antitrypsin deficiency | 3.7 | 9 | Citations (PDF) |
| 54 | Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI‐PDFF in NAFLD | 3.7 | 16 | Citations (PDF) |
| 55 | Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase | 10.1 | 86 | Citations (PDF) |
| 56 | Clinical utility of liver fat quantification for determining cardiovascular disease risk among patients with type 2 diabetes | 3.7 | 24 | Citations (PDF) |
| 57 | Response to Paik et al. on the disease burden of NAFLD | 25.2 | 4 | Citations (PDF) |
| 58 | Chemoprevention in hepatocellular carcinoma | 0.6 | 1 | Citations (PDF) |
| 59 | Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology | 45.9 | 168 | Citations (PDF) |
| 60 | Ramipril for the Treatment of COVID-19: RAMIC, a Randomized, Double-Blind, Placebo-Controlled Clinical Trial | 3.3 | 4 | Citations (PDF) |
| 61 | The silent burden of non‐alcoholic fatty liver disease in the elderly: A global burden of disease analysis | 3.7 | 30 | Citations (PDF) |
| 62 | MEFIB‐Index and MAST‐Score in the assessment of hepatic decompensation in metabolic dysfunction‐associated steatosis liver disease—Individual participant data meta‐analyses | 3.7 | 18 | Citations (PDF) |
| 63 | Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study | 4.2 | 7 | Citations (PDF) |
| 64 | Natural History and Hepatocellular Carcinoma Risk in Untreated Chronic Hepatitis B Patients With Indeterminate Phase | 6.0 | 115 | Citations (PDF) |
| 65 | Substantial gaps in evaluation and treatment of patients with hepatitis B in the US | 4.2 | 46 | Citations (PDF) |
| 66 | Meta‐analysis and systematic review: Prevalence, graft failure, mortality, and post‐operative thrombosis in liver transplant recipients with pre‐operative portal vein thrombosis | 1.7 | 24 | Citations (PDF) |
| 67 | A Diagnostic Test Meta‐Analysis Evaluating Imaging‐Based and Blood Biomarker–Based Assessment Tools for Fibrosis After Liver Transplantation | 2.5 | 9 | Citations (PDF) |
| 68 | Global Prevalence, Risk Factors, and Outcomes of Depression After Liver Transplant: A Systematic Review and Meta-analysis | 1.1 | 9 | Citations (PDF) |
| 69 | 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis | 6.0 | 583 | Citations (PDF) |
| 70 | Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: A prospective study | 3.7 | 55 | Citations (PDF) |
| 71 | Review article: current and emerging therapies for the management of cirrhosis and its complications | 3.7 | 35 | Citations (PDF) |
| 72 | Meta‐analysis: analysis of mechanistic pathways in the treatment of
non‐alcoholic
steatohepatitis. Evidence from a Bayesian network
meta‐analysis | 3.7 | 27 | Citations (PDF) |
| 73 | Global and regional long‐term survival following resection for HCC in the recent decade: A meta‐analysis of 110 studies | 4.5 | 77 | Citations (PDF) |
| 74 | Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease | 2.9 | 54 | Citations (PDF) |
| 75 | Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12 620 736 Individuals | 3.3 | 62 | Citations (PDF) |
| 76 | Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis | 27.4 | 274 | Citations (PDF) |
| 77 | A systematic review and meta-analysis on the impact of pre-existing and new-onset atrial fibrillation on outcomes before and after liver transplantation | 2.5 | 16 | Citations (PDF) |
| 78 | The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease | 8.8 | 76 | Citations (PDF) |
| 79 | Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer | 25.2 | 473 | Citations (PDF) |
| 80 | Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus | 6.6 | 42 | Citations (PDF) |
| 81 | Shared Mechanisms between Cardiovascular Disease and NAFLD | 3.2 | 34 | Citations (PDF) |
| 82 | Impact of advanced practice providers on characteristics and quality of care of patients with chronic hepatitis B | 3.7 | 6 | Citations (PDF) |
| 83 | Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors | 45.9 | 436 | Citations (PDF) |
| 84 | Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States | 6.6 | 51 | Citations (PDF) |
| 85 | Epidemiology of COVID‐19: A systematic review and meta‐analysis of clinical characteristics, risk factors, and outcomes | 3.7 | 573 | Citations (PDF) |
| 86 | Effects of Cirrhosis and Diagnosis Scenario in Metabolic-Associated Fatty Liver Disease-Related Hepatocellular Carcinoma | 4.5 | 26 | Citations (PDF) |
| 87 | A Meta-Analysis on the Rate of Hepatocellular Carcinoma Recurrence after Liver Transplant and Associations to Etiology, Alpha-Fetoprotein, Income and Ethnicity | 2.5 | 43 | Citations (PDF) |
| 88 | Defining Age-Related Thresholds for ALT and the Risk of Confounders | 6.0 | 0 | Citations (PDF) |
| 89 | A Time-Based Meta-Analysis on the Incidence of New Onset Diabetes after Liver Transplantation | 2.5 | 9 | Citations (PDF) |
| 90 | Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study | 3.8 | 68 | Citations (PDF) |
| 91 | Differential characteristics and outcomes of Asian and non‐Asian patients with HBV‐related hepatocellular carcinoma | 4.0 | 27 | Citations (PDF) |
| 92 | Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice | 10.1 | 39 | Citations (PDF) |
| 93 | Letter to the Editor: Hepatocellular Carcinoma Surveillance in Cirrhosis Patients: Is the Real‐World Situation Even Worse Than Reported? | 10.1 | 5 | Citations (PDF) |
| 94 | HBV‐related hepatocellular carcinoma: A call to improve surveillance and linkage to care | 4.0 | 3 | Citations (PDF) |
| 95 | A network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis | 4.2 | 38 | Citations (PDF) |
| 96 | Letter: hepatocellular carcinoma risk in patients with non‐selective beta blockers | 3.7 | 2 | Citations (PDF) |
| 97 | Cost‐effectiveness of HCC surveillance among HCV patients after sustained virological response with direct‐acting antivirals | 4.0 | 0 | Citations (PDF) |
| 98 | Impact of COVID-19 on Liver Transplantation in Hong Kong and Singapore: A Modelling Study | 3.4 | 4 | Citations (PDF) |
| 99 | Controversies in Treating Chronic Hepatitis B virus | 3.5 | 1 | Citations (PDF) |
| 100 | Novel albumin, bilirubin and platelet criteria for the exclusion of high-risk varices in compensated advanced chronic liver disease: A validation study | 1.8 | 4 | Citations (PDF) |
| 101 | Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy | 5.6 | 17 | Citations (PDF) |
| 102 | Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg) | 3.7 | 29 | Citations (PDF) |
| 103 | A Multiethnic Asian Perspective of Presumed Consent for Organ Donation: A Population-Based Perception Study | 2.7 | 8 | Citations (PDF) |
| 104 | A meta‐analysis of the cumulative incidence, risk factors, and clinical outcomes associated with chronic kidney disease after liver transplantation | 2.0 | 15 | Citations (PDF) |
| 105 | Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study | 4.2 | 18 | Citations (PDF) |
| 106 | ALT Levels for Asians With Metabolic Diseases: A Meta‐analysis of 86 Studies With Individual Patient Data Validation | 4.5 | 25 | Citations (PDF) |
| 107 | Extraction of intra-biliary hepatocellular carcinoma by endoscopic retrograde cholangiopancreatography | 2.2 | 2 | Citations (PDF) |
| 108 | Liver Care and Surveillance: The Global Impact of the COVID‐19 Pandemic | 4.5 | 53 | Citations (PDF) |
| 109 | Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis | 22.9 | 779 | Citations (PDF) |
| 110 | Radiofrequency ablation versus repeat resection for recurrent hepatocellular carcinoma (≤ 5 cm) after initial curative resection | 3.6 | 45 | Citations (PDF) |
| 111 | Hepatitis B: Who to treat? A critical review of international guidelines | 4.0 | 32 | Citations (PDF) |
| 112 | Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention | 45.9 | 1,615 | Citations (PDF) |
| 113 | Life After s Loss: Impact of Hepatitis B s Antigen Loss on Future Patient Outcomes | 1.3 | 4 | Citations (PDF) |
| 114 | A murine model demonstrating reversal of structural and functional correlates of cirrhosis with progenitor cell transplantation | 3.4 | 13 | Citations (PDF) |
| 115 | Editorial on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study” | 8.8 | 2 | Citations (PDF) |
| 116 | Broadening PEth testing for alcohol exposure in the Asia-Pacific region | 4.2 | 2 | Citations (PDF) |
| 117 | Incidence of Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Reconstructed Individual Patient Data Meta-Analysis | 6.0 | 3 | Citations (PDF) |
| 118 | Impact of Concurrent Steatotic Liver Disease and Chronic Hepatitis B on Treatment Response to Nucleos(t)ide Analogs | 1.9 | 0 | Citations (PDF) |
| 119 | Meta‐Analysis: Utilisation of Hepatocellular Carcinoma Surveillance | 3.7 | 3 | Citations (PDF) |
| 120 | Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction–Associated Steatotic Liver Disease (
MASLD
) | 3.7 | 5 | Citations (PDF) |
| 121 | Plasma inflammatory proteome profiles identify MASLD among children with overweight or obesity | 9.4 | 0 | Citations (PDF) |
| 122 | Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities | 16.8 | 6 | Citations (PDF) |
| 123 |
PNPLA3
Genotype and Clinical Factors Impact Hepatocellular Carcinoma Risk: Findings From a Prospective Cohort Study | 3.7 | 3 | Citations (PDF) |
| 124 | Network Meta‐Analysis: Comparison of Pharmacological Therapies in Compensated Metabolic Dysfunction‐Associated Steatohepatitis Cirrhosis for Fibrosis Regression and
MASH
Resolution | 3.7 | 1 | Citations (PDF) |
| 125 | Rethinking “Safe” Drinking: A Review of the Carcinogenic Risks of Alcohol Consumption | 0.6 | 0 | Citations (PDF) |
| 126 | Abstract 936: Temporal dependency of STAT3 signaling dictates hepatocarcinogenesis in metabolic dysfunction-associated steatohepatitis. | 3.8 | 0 | Citations (PDF) |
